Madrigal Pharmaceuticals (NASDAQ:MDGL) vs. Rani Therapeutics (NASDAQ:RANI) Financial Comparison

Rani Therapeutics (NASDAQ:RANI) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Rani Therapeutics and Madrigal Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1	0	4	1	2.83
Madrigal Pharmaceuticals	1	2	15	0	2.78

Rani Therapeutics presently has a consensus price target of $8.75, suggesting a potential upside of 911.21%. Madrigal Pharmaceuticals has a consensus price target of $699.64, suggesting a potential upside of 29.30%. Given Rani Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Rani Therapeutics is more favorable than Madrigal Pharmaceuticals.

Institutional and Insider Ownership

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Rani Therapeutics and Madrigal Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63 million	74.00	-$29.67 million	($0.27)	-3.20
Madrigal Pharmaceuticals	$958.40 million	13.04	-$288.28 million	($12.89)	-41.98

Rani Therapeutics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Rani Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, meaning that its stock price is 198% less volatile than the S&P 500.

Profitability

This table compares Rani Therapeutics and Madrigal Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-104.60%	-65.17%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Summary

Rani Therapeutics beats Madrigal Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.